Current approaches to overcome bacterial resistance

Drugs of the Future

Volumn 22, Issue 3, 1997, Pages 271-284

  Setti, E L ^a   Quattrocchio, L ^b   Micetich, R G ^a  

^a NAEJA Pharmaceutical Inc   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BOXAZOMYCIN; EPEREZOLID; GE 2270A; GE 37468A; LANTABIOTIC; LINEZOLID; LIPOSIDOMYCIN; MERSACIDIN; MUREIDOMYCIN A; PRISTINAMYCIN; PSEUDOMONIC ACID; RAMOPLANIN; TUNICAMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; CELL WALL; DRUG DESIGN; DRUG RESISTANCE; REVIEW;

EID: 0030923633     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (162)

1. Neu, H.C. The crisis of antibiotic resistance. Science 1992, 257: 1064-72.
2. Cohen, M.L. Epidemiology of drug resistance: Implications for a post-antimicrobial era. Science 1992, 257: 1050-5.
3. Voss, A., Doebbeling, B. The world-wide prevalence of methicillin-resistant S. aureus. Int J Antimicrob Agents 1995, 5: 101-6.
4. Yoshida, R., Kaku, M., Kohno, S. et al. Trends in antimicrobial resistant Streptococcus pneumoniae in Japan. Antimicrob Agents Chemother 1995, 39: 1196-8.
5. (a) Bloom, B. Back to frightening future. Nature 1992, 358: 538-9.
6. (b) Culliton, B. Drug-resistant TB may bring epidemic. Nature 1992, 356: 473.
7. (a) Leclerq, R., Derlot, E., Duval, J., Courvalin, P. Plasmid mediated resistance to vancomycin-teicoplanin in Enterococcus faecium. New Engl J Med 1988, 319: 157-61.
8. (b) Billot-Klein, D., Gutman, L., Collatz, E., Van Heijenoort, J. Analysis of peptidoglycan precursors in vancomycin-resistant enterococci. Antimicrob Agents Chemother 1992, 36: 1487-90.
9. Marr, J.J., Moffet, H.L., Kunin, C.M. Guidelines for improving the use of antimicrobial agents in hospitals: A statement by the Infectious Disease Society of America. J Infect Dis 1988, 157: 869-76.
10. Goldman, D.A., Weinstein, R.A., Wenzel, R.P. et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA 1996, 275: 234-40.
11. Chopra, I., Hodgson, J., Metcalf, B., Poste, G. New approaches to the control of infections caused by antibiotic-resistant bacteria. JAMA 1996, 275: 401-3.
12. Souza, N.J., Ganguli, B.N., Reden, J. Strategies in discovering drugs from natural sources. Annu Rep Med Chem 1982, 17: 301-10.
13. Gootz, T.D. Discovery and development of new antimicrobial agents. Clin Microbiol Rev 1990, 3: 13-31.
14. Hutchinson, C.R., Borell, C.W., Otten, S.L., Stutzman-Engwall, K.J., Wang, Y. Drug discovery and development through the genetic engineering of antibiotic-producing microorganisms. J Med Chem 1989, 32: 929-37.
15. Behrens, O.K., Corse, J., Edwards, J.P. et al. Biosynthesis of penicillins. IV. New crystalline biosynthetic penicillins. J Biol Chem 1948, 175: 793.
16. Hutchinson, C.R. Prospect for the discovery of new (hybrid) antibiotics by genetic engineering of antibiotic-producing bacteria. Med Res Rev 1988, 8: 557-67.
17. Stapley, E.O., Jackson, M., Hernandez, S. et al. Cephamycins, a new family of β-lactam antibiotics. Antimicrob Agents Chemother 1972, 2: 122-31.
18. Stampley, E.O., Birnbaum, J., Miller, A.K., Wallick, H., Hendlin, D., Woodruff, H.B. Cefoxitin and cephamycins: Microbiological studies. Rev Infect Dis 1979, 1: 73-87.
19. (a) Blondelle, S.E., Pérez-Payá, E., Houghten, R.A. Synthetic combinatorial libraries: Novel discovery strategy for identification of antimicrobial agents. Antimicrob Agents Chemother 1996, 40: 1067-71, and references therein.
20. (b) Still, W.C. Discovery of sequence-selective peptide binding by synthetic receptors using encoded combinatorial libraries. Acc Chem Res 1996, 29: 155-63, and references therein.
21. Rybak, M.J., McGrath, B.J. Combination antimicrobial therapy for bacterial infections, guidelines for the clinician. Drugs 1996, 52 (3): 390-405.
22. (a) Murray, H.W. Cytokines as antimicrobial therapy for the T cell-deficient patient: Prospect for treatment of nonviral opportunistic infections. Clin Infect Dis 1993, 17 (Suppl. 2): s407-13, and references therein.
23. (b) Murray, H.W. Gamma interferon, cytokine-induced macrophage activation and antimicrobial host defense: In vitro, in animal models, and in humans. Diagn Microbiol Infect Dis 1990, 13: 411-21.
24. (c) Babineau, T.J., Marcello, P., Forse, R.A. Randomized phase I/II trial of a macrophage-specific-immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg 1994, 220: 601-9, and references therein.
25. a) Corbeil, B.L. Strategies to overcome bacterial virulence mechanisms: An overview. In: Virulence Mechanisms of Bacterial Pathogens. Roth, J.A. (Ed.). ASM Press: Washington, DC 1988, 301-10.
26. (b) Monto, A.S., Terpenning, M.S. The value of influenza and pneumococcal vaccines in the elderly. Drugs Aging 1996, 8: 445-51.
27. (c) Mills, O.F., Rhoads, G.G. The contribution of the case-control approach to vaccine evaluation: Pneumococcal and Haemophilus influenzae type B PRP vaccines. J Clin Epidemiol 1996, 49: 631-6.
28. (a) Davies, J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994, 264: 375-81.
29. (b) Mayer, K.H., Opal, S.M., Madeiros, A.A. Mechanism of antibiotic resistance. In: Principles and Practice of Infectious Diseases, 3rd Ed. Mandell, G.L., Douglas, R.G. Jr., Bennett, J.E. (Eds.). Churchill Livingstone: New York 1990, 218-26.
30. (a) Benveniste, R., Davies, J. Aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria. Proc Natl Acad Sci USA 1973, 70: 2276-80.
31. (b) Davies, J., Smith, D.I. Plasmidresistance to antimicrobial agents. Ann Rev Microbiol 1978, 32: 469-518.
32. Spratt, B. Resistance to antibiotic mediated by target alterations. Science 1994, 264: 388-93.
33. Frère, J.M., Nguyen-Distèche, M., Coyette, J., Joris, B. Mode of action: Interaction with the penicillin binding proteins. In: The Chemistry of β-Lactams. Page, M.I. (Ed.). Blackie Academic and Professional: New York 1992, 148-97.
34. (a) Waley, S.G. Beta-lactamases: Mechanism of action. In: The Chemistry of β-lactams. Page, M.I. (Ed.). Blackie Academic and Professional: New York 1992, 198-228.
35. (b) Coulton, S.,. François, I. β-Lactamases: Targets for drug design. In: Progressin Medicinal Chemistry. Ellis, G.P., Luscombe, D.K. (Eds.). Elsevier Science Amsterdam 1994, 31: 297-349.
36. Brown, A.G., Butterworth, D., Cole, M. et al. Naturally-occurring β-lactamase inhibitor with antibacterial activity. J Antibiot 1976, 29: 668-9
37. Reading, C., Cole, M. Clavulanic acid: Aβ-lactamase-inhibiting β-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 1977, 11: 852-7.
38. English, A.R., Retsema, J.A., Girard, A.E., Lynch, J.E., Barth, W.E. CP-45,899, a β-lactamase inhibitor that extends the antibacterial spectrum of β-lactams: Initial bacteriological characterization. Antimicrob Agents Chemother 1978, 14: 414-9.
39. (a) Micetich, R.G., Maiti, S.N., Spevak, P. et al. Synthesis and β-lactamase inhibitory properties of 2β-[(1,2,3-triazol-1-yl)methyl]-2α-methylpenam-3α-carboxilic acid 1,1-dioxide and related triazolyl derivatives. J Med Chem 1987, 30: 1469-74.
40. (b) Aronoff, S.C., Jacobs, M.R., Johenning, S., Yarrabe, S. Comparative activities of the β-lactamase inhibitor YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and Pseudomonas. J Antimicrob Chemother 1986, 18: 177-84.
41. (a) Chopra, I. The tetracyclines. In: Handbook of Experimental Pharmacology. Hlavaka, J.J., Boothe, J.H. (Eds.). Springer-Verlag: Berlin 1985, 317-91.
42. (b) Schnappinger, D., Hillen, W. Tetracyclines: Antibiotic action, uptake and resistance mechanisms. Arch Microbiol 1996, 165: 359-69.
43. (a) Sum, P.-E, Lee, V.J., Testa, R.T. et al. Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J Med Chem 1994, 37: 184-8.
44. (b) Barden, C.T., Buckwalter, B.L., Testa, R.T., Petersen, P.J., Lee, V.J. Glycylcyclines. 3. 9-Aminodoxycyclinecarboxamides. J Med Chem 1994, 37: 3205-11.
45. Testa, R.T., Petersen, P.J. et al. In vitro and in vivo antibacterial activity of glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993, 37: 2270-7.
46. Nelson, M.L., Park, B.H., Andrews, J.S., Georgian, V.A., Thomas, R.C., Levy, S.B. Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxy tetracyclines. J Med Chem 1993, 36: 370-7.
47. Miller, G.H., Chiu, P.J.S., Waitz, J.A. Biological activity of SCH 21420, the 1-N-α-hydroxy-13-aminopropionyl derivative of gentamicin. J Antibiot 1978, 31: 688-96.
48. Jones, R.N. Isepamicin(SCH21420, 1-N-HAPA gentamicin B): Microbiological characteristics including antimicrobial potency and spectrum of activity. J Chemother 1995, 7 (Suppl. 2): 7-16.
49. Dever, L.A., Dermody, T.S. Mechanism of bacterial resistance to antibiotics. Arch Intern Med 1991, 151: 886-95, and references therein.
50. Lambert, T., Gerbaud, G., Galimand, M. Courvalin, P. Characterization of Acinetobacter haemolyticus AAC(6′)-lg gene encoding an aminoglycoside 6″-N-acetyltransferase which modifies amikacin. Antimicrob Agents Chemother 1993, 37: 2093-100.
51. Miller, G.H., Sabatelli, F.J., Naples, L., Hare, R.S., Shaw, K.J. The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin - A new broad-spectrum aminoglycoside. J Chemother 1995, 7 (Suppl. 2): 31-44.
52. Kondo, S., Iinuma, K. Yamamoto, H., Maeda, K., Umezawa, H. Synthesis of 1-N-{(S)-4-amino-2-hydroxybutyryl)-kanamycin B and -3′,4′-dideoxykanamycin B active against kanamycin-resistant bacteria. J Antibiot 1973, 26: 412-5.
53. Hotta, K., Zhu, C.B., Ogata, T. et al. Enzymatic 2′-N-acetylation of arbekacin and antibiotic activity of its product. J Antibiot 1996, 49: 458-64.
54. (a) Barna, J.C.J., Williams, D.H. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol 1984, 38: 339-57.
55. (b) Reynolds, P.E. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989, 8: 943-50.
56. (a) Handwerger, S., Pucci, M.J., Volk, K.J., Liu, J., Lee, M.S. The cytoplasmic peptidoglycan precursor of vancomycin-resistant Enterococcus faecalis terminates in lactate. J Bacteriol 1992, 174: 5982-4.
57. (b) Messer, J., Reynolds, P.E. Modified peptidoglycan precursors produced by glycopeptide-resistant enterococci. FEMS Microbiol Lett 1992, 94: 195-200.
58. Allen, N.E., Hobbs, J.N. Jr., Nicas, T.I. Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic. Antimicrob Agents Chemother 1996, 40: 2356-62.
59. Nicas, T.I., Mullen, D.L., Flokowitsch, J.E. et al. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob Agents Chemother 1996, 40: 2194-9.
60. (a) Nikaido, H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989, 33: 1831-6.
61. (b) Godfrey, A.J., Bryan, L.E. Penetration of β-lactam through Pseudomonas aeruginosa porin channels. Antimicrob Agents Chemother 1987, 31: 1216-21.
62. (c) Hancock, R.E.W., Woodruff, W.A. Roles of porin and β-lactamase in β-lactam resistance of Pseudomonas aeruginosa. Rev Infect Dis 1988, 10: 770-5.
63. Nikaido, H. Prevention of drug access to bacterial targets: Role of permeability barriers and active efflux. Science 1994, 264: 382-9.
64. Nikaido, H., Vaara, M. Molecular basis of bacterial outer membrane permeability. Microbiol Rev 1985, 45: 1-32.
65. (a) Fukuoka, T., Ohya, S., Narita, T. et al. Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother 1993, 37: 322-7.
66. (b) Fung-Tomc, J.C., Huczko, E., Banville, J. et al. Structure-activity relationship of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995, 39: 394-9.
67. (c) Fung-Tomc, J.C., Gradelski, E., Kolek, B. et al. Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2. Antimicrob Agents Chemother 1995, 39: 386-93.
68. (a) Trias, J., Nikaido, H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990, 34: 52-7.
69. (b) Sumita, Y., Eguchi, Y., Fukasawa, M. et al. The effect of 1β-methyl and imidoyl substituents on the antipseudomonal activity of carbapenems. J Antibiot 1993, 46: 1629-32.
70. (a) Diarra, M.S., Lavoie, M.C., Jacques, M. et al. Species selectivity of new siderophore-drug conjugates that use specific iron uptake for entry into bacteria. Antimicrob Agents Chemother 1996, 40: 2610-7.
71. 5-hydroxy-L-ornithine-derived siderophore-β-lactam conjugates: Iron transport-mediated drug delivery. J Med Chem 1991, 34: 968-78.
72. (c) Miller, M.J., Malouin, F. Microbial iron chelators as drug delivery agents: The rational design and synthesis of siderophore-drug conjugates. Acc Chem Res 1993, 26: 241-9.
73. Winkelman, G., Ed. Handbook of Microbial Iron Chelates. CRC Press: Boca Raton 1991.
74. Postle, K. TonB and the Gram-negative dilemma. Mol Microbiol 1990, 4: 2019-25.
75. (a) Brochu, A., Brochu, N., Nicas, T.I. et al. Mode of action and inhibitory activities of new siderophore-β-lactam conjugates that use specific iron uptake pathways for entry into bacteria. Antimicrob Agents Chemother 1992, 36: 2166-75.
76. (b) Minnick, A.A., McKee, J.A., Dolence, K.E., Miller, M.J. Iron transport-mediated antibacterial activity of and development of resistance to hydroxamate and catechol siderophore-carbacephalosporin conjugates. Antimicrob Agents Chemother 1992, 36: 840-50.
77. (a) Nikaido, H., Rosenberg, E.Y. Cir and Fiu proteins in the outer membrane of Escherichia coli catalyze transport of monomeric catechol: Study with β-lactam antibiotic containing catechol and analogous groups. J Bacteriol 1990, 172: 1361-7.
78. (b) Tatsumi, Y., Maejima, T., Mitsuhashi, S. Mechanism of tonB-dependent transport of KP-736, a 1,5-dihydroxy-4-pyridone-substituted cephalosporin, into Escherichia coli K-12 cells. Antimicrob Agents Chemother 1995, 39: 613-9.
79. (c) Silley, P., Griffiths, J.W., Monsey, D., Harris, A.M. Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system. Antimicrob Agents Chemother 1990, 34: 1806-8.
80. (d) Toyosawa, T., Miyazaki, S., Tsuji, A., Yamaguchi, K., Goto, S. In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin. Antimicrob Agents Chemother 1993, 37: 60-6.
81. (e) Kim, Y.-Z., Lim, J.-C, Yeo, J.-H. et al. Synthesis and antibacterial activities of novel C(7)-catechol-substituted cephalosporins (II). J Antibiot 1996, 49: 499-501.
82. Ofek, I., Cohen, S., Rahmani, R. et al. Antibacterial synergism of polymyxin B nonapeptide and hydrophobic antibiotics in experimental Gram-negative infections in mice. Antimicrob Agents Chemother 1994, 38: 374-7.
83. Silver, L.L., Bostian, K.A. Discovery and development of new antibiotics: The problem of antibiotic resistance. Antimicrob Agents Chemother 1993, 37: 377-83.
84. Setti, E.L., Micetich, R.G. Modern drug design and lead discovery: An overview. Curr Med Chem 1996, 3: 317-24.
85. (a) Niu, W.W., Neu, H.C. Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin. Antimicrob Agents Chemother 1991, 35: 998-1000.
86. (b) Brötz, H., Bierbaum, G., Markus, A. Molitor, E., Sahl, H.G. Mode of action of the antibiotic mersacidin: Inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrob Agents Chemother 1995, 39: 714-9.
87. (c) Chatterjee, S., Chatterjee, D.K., Jani, R.H. et al. Mersacidin, a new antibiotic from Bacillus, in vitro and in vivo antibacterial activity. J Antibiot 1992, 45: 839-45.
88. Ganguli, B.N., Chatterjee, S., Chatterjee, D.K. et al. 29th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Houston) 1989, Abst 413.
89. (a) Somner, E.A., Reynolds, P.E. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob Agents Chemother 1990, 34: 413-9.
90. (b) Jones, R.N., Barry, A. In vitro evaluation of ramoplanin (A 16686 or MDL 62198), a new depsipeptide complex for potential topical use. Diagn Microbiol Infect Dis 1989, 12: 279-82.
91. Brandish, P.E., Kimura, K.I., Inukai, M., Southgate, R., Lonsdale, J.T., Bugg, T.D.H. Mode of action of tunicamycin, liposidomycin B, and mureidomycin A: Inhibition of phospho-N-acetylmuramyl-pentapeptide translocase from Escherichia coli. Antimicrob Agents Chemother 1996, 40: 1640-4.
92. (a) Brandish, P.E., Burnham, M.K., Lonsdale, J.T. Southgate, R., Inukai, M. Bugg, T.D.H. Slow-binding inhibition of phospho-N-acetylmuramyl-pentapeptide translocase (Escherichia coli) by mureidomycin A. J Biol Chem 1996, 271, 7609-14.
93. (b) Isono, F., Inukai, M. Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis. Antimicrob Agents Chemother 1991, 35: 234-6.
94. (c) Inukai, M. Isono, F., Takatsuki, A. Selective inhibition of the bacterial translocase reaction in peptidoglycan synthesis by mureidomycins. Antimicrob Agents Chemother 1993, 37: 980-3.
95. (a) Slee, A.M., Wuonola, M.A., McRipley, R.J. et al. Oxazolidinones, a new class of synthetic antibacterial agents: In vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother 1987, 31: 1791-7.
96. (b) Eustice, D., Feldman, P.A., Zajac, I., Slee, A.M. Mechanism of action of DuP 721: Inhibition of an early event in protein synthesis. Antimicrob Agents Chemother 1988, 32: 1218-22.
97. (a) Mason, E.G. Jr., Lamberth, L.B. Kaplan, S.L. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1996, 40: 1039-40.
98. (b) Kaatz, G.W., Seo, S.M. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermis. Antimicrob Agents Chemother 1996, 40, 799-801.
99. (c) Ford, C.W., Hamel, J.C., Wilson, D.M. et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents, against experimental bacterial infections. Antimicrob Agents Chemother 1996, 40: 1508-13.
100. (d) Zurenko, G.E., Yagi, B.H., Schaadt, R.D. et al. In vitro activities of U-100592 and U-100766. novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996, 40: 839-45.
101. (a) Janbon, N., Brunei, D., Bertrand, A., Michel-Briand. Lapristinamycin (7293 RP) antibiotique antistaphylococcique. Etude comparative in-vitro, première expérience clinique. Sem Thèr 1962, 38: 25-33.
102. (b) Vannuffel, P., Cocito, C. Mechanism of action of streptogramin and macrolides. Drugs 1996, 51 (Suppl. 1): 20-30.
103. Brumfitt, W., Hamilton-Miller, J.M.T., Shah, S. In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against Gram-positive bacteria. J Antimicrob Chemother 1992, 30 (Suppl. A): 29-37.
104. (a) Goto, S., Miyazaki, S., Kaneko, Y. The in-vitro activity of RP 59500 against Gram-positive cocci. J Antimicrob Chemother 1992, 30 (Suppl. A): 25-8.
105. (b) Verhaegen, J., Verbist, L. Comparative in-vitro activity of RP 59500. J Antimicrob Chemother 1992, 30 (Suppl. A): 39-44.
106. (c) Fremaux, A., Sissia, R., Cohen, R., Geslin, P. In-vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae. J Antimicrob Chemother 1992, 30 (Suppl. A): 19-23.
107. (d) Finch, R.G. Antibacterial activity of quinupristin/dalfopristin. Drugs 1996, 51 (Suppl. 1): 31-7.
108. (a) Jorgensen, J.H., McElmeel, M.L., Trippy, C.W. Activity of the oral streptogramin antibiotic RP106972 against Haemophilus influenzae. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18. New Orleans) 1996, Abst F229.
109. (b) Pankuch, G., Jacobs, M., Appelbaum, P. Antipneumococcal activity of the oral streptogramin RPR 106972. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F228.
110. Selva, E., Beretta, G., Montanini, N. et al. Antibiotic GE2270A: A novel inhibitor of bacterial protein synthesis. J Antibiot 1991, 44: 693-701.
111. (a) Goldstein, B.P., Berti, M., Ripamonti, F., Resconi, A., Scotti, R., Denaro, M. In vitro antimicrobial activity of a new antibiotic. MLD 62,879 (GE2270A). Antimicrob Agents Chemother 1993, 37: 741-5.
112. (b) King, A., Bethune, L., Phillips, I. In vitro activity of MDL 62,879 (GE2270A) against aerobic Gram-positive and anaerobic bacteria. Antimicrob Agents Chemother 1993, 37: 746-9.
113. (a) Ferrari, P., Colombo, L. Stella, S., Selva, E., Zerilli, L.F. Antibiotic GE37468A: A novel inhibitor of bacterial protein synthesis. II. Structure elucidation. J Antibiot 1995, 48: 1304-11.
114. (b) Stella, S., Montanini, N., LeMonnier, F. et al. Antibiotic GE37468A: A new inhibitor of bacterial protein synthesis. I. Isolation and characterization. J Antibiot 1995, 48: 780-6.
115. Hughes, J., Mellows, G. Interaction of pseudomonic acid A with Escherichia coli B isoleucyl-tRNA synthetase. Biochem J 1978, 191: 209-19.
116. Bactobran. Proceedings of an International Symposium. Dobson, R.L., Leyden, J.J., Noble, W.C., Price, J.D. (Eds.). Elsevier: Amsterdam 1985.
117. (a) Broom, N.J.P., Cassels, R., Cheng, H.Y. et al. The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity. J Med Chem 1996, 39: 3596-600.
118. (b) Broom, N.J.P., Elder, J.S., Hannan, P.C.T. et al. The chemistry of pseudomonic acid part 14. Synthesis and in vivo biological activity of heterocyclic substituted oxazole derivatives. J Antibiot 1995, 48: 1336-44.
119. (a) Stier, M.A., Domagala, J.M., Gogliotti, R.D. et al. Synthesis and antibacterial activity of new boxazomycin derivatives: The structure-activity relationship of the A ring. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F21.
120. (b) Song, Y., Domagala, J.M., Turner, W.R. et al. Boxazomycin analogues as new antibacterial agents: Synthesis and structure-activity relationship. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F22.
121. (c) Miller, P.F., Johnson, G., Gracheck, S.J. et al. Determination of the mechanism of action of boxazomycin B, a Gram-positive specific antibacterial agent. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F23.
122. (a) Zasloff, M. Magainins, a class of antimicrobial peptide from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 1987, 84: 5449-53.
123. (b) Zasloff, M., Martin, B., Chen, H.-C. Antimicrobial activity of synthetic magainin peptides and several analogues. Proc Natl Acad Sci USA 1988, 85: 910-3.
124. (c) Huang, C.M., Chen, H.C., Zierdt, C.H. Magainin analogs effective against pathogenic protozoa. Antimicrob Agents Chemother 1990, 34: 1824-6.
125. Darveau, R.P., Cunningham, M.D., Seachord, C.L. et al. β-Lactam antibiotics potentiate magainin 2 antimicrobial activity in vitro and in vivo. Antimicrob Agents Chemother 1991, 35: 1153-9.
126. Hultmark, D., Steiner, H., Rasmuson, T., Boman, H.G. Insect immunity. Purification and properties of three inducible bactericidal proteins from hemolymph of immunized pupae of Hyalophora cecropia. Eur J Biochem 1980, 106: 7-16.
127. (a) Larrick, J.W., Wright, S.C. Cationic antimicrobial proteins. Drugs Fut 1996, 21: 41-8.
128. (b) Moore, A.J., Beazley, W.D., Bibby, M.C., Devine, D.A. Antimicrobial activity of cecropins. J Antimicrob Chemother 1996, 37: 1077-89.
129. Lehrer, R.I., Lichtenstein, A.K., Ganz, T. Defensins: Antimicrobial and cytotoxic peptide of mammalian cells. Ann Rev Immunol 1993, 11: 105-28.
130. (a) Steinberg, D.A., Hurst, M.A., Fuji, C.A. Broad spectrum antimicrobial activity of protegrin peptide. 36th Intersci Conf Antimicrob Agentes Chemother (Sept 15-18, New Orleans) 1996, Abst F243.
131. (b) Kung, A.H.C., Fiddes, J.C., Loury, D.J., Ho, J.F., Cheng, F.-C. Protegrins protect mice from systemic infection by antibiotic resistant pathogens. 36th Intersci Conf Antimicrob Agents (Sept 15-18, New Orleans) 1996, Abst F244.
132. (c) Steinberg, D.A., Hurst, M.A., Keve, S.G., Chao, D.H. In vitro efficacy of protegrins against Helicobacter pylori. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F245.
133. (a) Hancock, R.E.W., Falla, T.J. Antimicrobial peptides: Broadspectrum antibiotics from nature. Clin Microbiol Infect 1996, 1: 226-9.
134. (b) Christensen, B., Fink, J., Merrifield, R.B., Mauzerall, D. Channel-forming properties of cecropins and related model compounds incorporated into planar lipid membranes. Proc Natl Acad Sci USA 1988, 85: 5072-6.
135. (a) Loebenger, D., Cacciapuoti, A., Naples, L. et al. Biological activity of SCH 27899 (EVE), an everninomicin antibiotic. 33th Ilntersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 456.
136. (b) Shlaes, D.M., Shlaes, J.H., Etter, L., Hare, R.S., Miller, G.H. SCH 27899 (EVE), an everninomicin active against multiply-resistant (R) enterococci and staphylococci. 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 460.
137. Sato, M., Tsuchiya, H., Miyazaki, T. et al. Antibacterial activity of hydroxychalcone against methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1996, 6: 227-31.
138. Iinuma, M., Tsuchiya, H., Sato, M. et al. Flavanones with potent antibacterial activity against methicillin-resistant Staphylococcus aureus. J Pharm Pharmacol 1994, 46: 892-5.
139. For a recent review about structure-based drug design see Böhm, H.-J., Klebe, G. What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs? Angew Chem Int Ed Engl 1996, 35: 2588-614, and references therein.
140. (a) Davies, G.M., Barrett-Bee, K.J., Jude, D.A. et al. (6S)-6-Fluoroshikimic acid, an antibacterial agent acting on the aromatic biosynthetic pathway. Antimicrob Agents Chemother 1994, 38: 403-6.
141. (b) Sutherland, J.K., Watkins, W.J., Bailey, J.P., Chapman, A.K., Davies, G.M. The synthesis of 6α-and 6β-fluoroshikimic acids. J Chem Soc Chem Commun 1989, 1386-7.
142. Hill, J.M., Yu, G., Shue, Y.-K., McCarthy, P., Wendler, P.A., Li, T. Synthesis and activity of a new class of antibacterial agents which target isoleucyl t-RNA synthetase. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F235.
143. (a) Uhlmann, E., Peyman, A. Antisense oligonucleotides: A new therapeutic principle. Chem Rev 1990, 90: 543-84.
144. (b) Milligan, B.F., Matteucci, M.D., Martin, J.C. Current concepts in antisense drug design. J Med Chem 1993, 36: 1923-37.
145. (c) Hyrup, B., Nielsen, P.E. Peptide nucleic acids (PNA): Synthesis, properties and potential applications. Bioorg Med Chem 1996, 4: 5-23.
146. Saylers, A.A., Whitt, D.D. Virulence factors that promote colonization. In: Bacterial Pathogenesis: A Molecular Approach. ASM Press: Washington, DC 1994, 30-46.
147. Aronson, M., Medalia, O., Schori, L., Mirelman, D., Sharon, N., Ofek, I. Prevention of colonization of the urinary tract of mice with Escherichia coli by blocking of bacterial adherence with methyl-α-D-mannopyranoside. J Infect Dis 1979, 139: 329-32.
148. Sharon, N., Lis, H., Carbohydrates in cell recognition. Sci Am Jan. 1993, 82-9.
149. Jarreton, O., Skrydstrup, T., Beau, J.-M. Thes tereospecific synthesis of methyl-α-C-mannobioside: A potential inhibitor of M. tuberculosis binding to human macrophages. Chem Commun 1996, 1661-2.
150. (a) Ogawa, Y., Lei, P.-S., Kovác, P. Synthesis of a functionalized hexasaccharide precursor of a glycoconjugate vaccine against cholera. Bioorg Med Chem Lett 1995, 5: 2283-6.
151. (b) Arencibia-Mohar, A., Madrazo-Alonso, O., Ariosa-Alvarez, A. et al. Synthesis of terminal disaccharides corresponding to Owaga and Inaba antigenic determinant from Vibrio cholerae. Carbohydr Lett 1995, 1: 173-8.
152. Bundle, D.R. The recognition of carbohydrate antigens by antibody at atomic resolution. Carbohydr Eur 1994, 22-30.
153. (a) Smith, P.W., Sollis, S.L., Howes, P.D. et al. Novel inhibitors of influenza sialidases related to GC167. Structure-activity, crystallographic and molecular dynamics studies with 4H-pyran-2-carboxylic acid 6-carboxamides. Bioorg Med Chem Lett 1996, 6: 2931-6.
154. (b) Bamford, M.J., Castro Pichel, J., Husman, W., Patel, B., Storer, R., Weir, N.G. Synthesis of 6-, 7-and 8-carbon sugar analogues of potent anti-influenza 2,3-didehydro-2,3-dideoxy-N-acetylneuraminic acid derivatives. J Chem Soc Perkin Trans I 1995, 1181-7.
155. Chandler, M., Conroy, R., Cooper, A.W.J. et al. Approaches to carbocyclic analogues of the potent neuraminidase inhibitor 4-guanidino-Neu5Ac2en. X-ray molecular structure of N-[(1S,2S,6R)-2-azido-6-benzyloxymethyl-4-formylcyclo-hex-3-enyl]acetamide. J Chem Soc Perkin Trans I 1995, 1189-91.
156. (a) von Itzstein, M., Wu, W.-Y, Kok, G.B. et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363: 418-23.
157. (b) Chandler, M., Bamford, M.J., Conroy, R. et al. Synthesis of the potent influenza neuraminidase inhibitor 4-guanidino Neu5Ac2en. X-ray molecular structure of 5-acetamido-4-amino-2,6-anhydro-3,4,5-trideoxy-D-erythro-L-gluconononic acid. J Chem Soc Perkin Trans I 1995, 1173-80.
158. Cohen, F.E., Gregoret, L.M., Amiri, P., Aldape, K., Railey, J., McKerrow, J.H. Arresting tissue invasion of a parasite by protease inhibitors chosen with the aid of computer modeling. Biochemistry 1991, 30: 11221-9.
159. Roychoudhury, S., Zeilinski, N.A., Ninfa, A.J. et al. Inhibitors of two component signal transduction systems: Inhibition of alignate gene activation in Pseudomonas aeruginosa. Proc Natl Acad Sci USA 1993, 90: 965-9.
160. (a) DiRita, V.J., Mekalanos, J.J. Genetic regulation of bacterial virulence. Annu Rev Genet 1989, 23: 455-82.
161. (b) Volz, K. Structural and functional conservation in response regulators In: Two-Component Signal Transduction. Hoch, J.A., Silhavy, T.J. (Eds.). ASM Press: Washington, DC 1995, 53-64.
162. Dziejman, M., Mekalanos, J.J. Two-component signal transduction and its role in the expression of bacterial virulence factors. In: Two-Component Signal Transduction, Hoch, J.A., Silhavy, T.J. (Eds.). ASM Press: Washington, DC 1995, 305-17.